The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany.
Rebecca HasseliU Müller-LadnerF KeilM BrollA DormannC FräbelW HermannC-J HeinmüllerB F HoyerF LöfflerF ÖzdenU PfeifferJ SaechT SchneidereitA SchlesingerA SchwartingChristof SpeckerG StapferM SteinmüllerK Storck-MüllerJ StrunkA ThieleK TriantafylliasD VagedesS WassenbergE WildenS ZeglamT SchmeiserPublished in: Rheumatology (Oxford, England) (2021)
The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician-patient relationship in times of a crisis.
Keyphrases
- sars cov
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- coronavirus disease
- peritoneal dialysis
- emergency department
- primary care
- public health
- healthcare
- oxidative stress
- prognostic factors
- electronic health record
- case report
- type diabetes
- stem cells
- machine learning
- clinical practice
- cell therapy
- artificial intelligence
- bone marrow
- juvenile idiopathic arthritis
- big data
- data analysis
- disease activity